Most Recent
Luxury car makers BMW and Mercedes-Benz are facing separate $100 million class actions over the alleged use of cheat devices on emissions tests.
Airservices Australia has succeeded in overturning a “manifestly unreasonable” $72,450 fine, but otherwise failed in its appeal of a decision which found it breached an enterprise agreement by withdrawing guidelines for standby shifts for air traffic controllers.
Insolvency practitioners are holding their breath as the High Court hears a case that could abolish a key rule used by liquidators in recouping payments to unsecured creditors at a time when the industry is bracing for a possible recession.
The public and political response to the Optus incident, including the federal government's announcement of urgent privacy law reform, suggests there may now be an appetite to test obstacles to data breach class actions, or for the government to legislate around them, say Allens lawyers Kate Austin, Valeska Bloch, Isabelle Guyot and Andrew Burns.
One Nation leader Pauline Hanson has been ordered to pay former colleague Brian Burston $250,000 for “seriously damaging” and malicious comments made in a Today Show interview.
The law firm that secured a $44.5 million settlement in a class action against Woolworths has won its full $14.5 million in costs, with a judge tossing the report of the referee he appointed to examine the fees, which he said appeared double what they should be.
Medical glove maker Ansell is facing a shareholder class action investigation over a January earnings downgrade that sent the company's share price plummeting.
A group member in the historic Black Saturday bushfire class action has filed a lawsuit alleging Maurice Blackburn was negligent in failing to bring a lawsuit over his work-related adenocarcinoma within time.
Fund manager Salter Brothers has been awarded more than $8 million in a breach of warranty suit against former Hendry Group boss Emma Hendry and related parties after they failed to comply with court orders in the case.
French drug giant Sanofi has appealed a decision giving American biopharmaceutical company Amgen the go-ahead for its patents for a cholesterol-lowering antibody that could be used to treat heart disease, diabetes, stroke and Alzheimer’s.